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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is one of the most common
malignancies in humans. The average 5-year survival rate is one of the lowest among aggressive
cancers, showing no significant improvement in recent years. When detected early, HNSCC has a
good prognosis, but most patients present metastatic disease at the time of diagnosis, which
significantly reduces survival rate. Despite extensive research, no molecular markers are currently
available for diagnostic or prognostic purposes.
Methods: Aiming to identify differentially-expressed genes involved in laryngeal squamous cell
carcinoma (LSCC) development and progression, we generated individual Serial Analysis of Gene
Expression (SAGE) libraries from a metastatic and non-metastatic larynx carcinoma, as well as from
a normal larynx mucosa sample. Approximately 54,000 unique tags were sequenced in three
libraries.
Results: Statistical data analysis identified a subset of 1,216 differentially expressed tags between
tumor and normal libraries, and 894 differentially expressed tags between metastatic and non-
metastatic carcinomas. Three genes displaying differential regulation, one down-regulated (KRT31)
and two up-regulated (BST2, MFAP2), as well as one with a non-significant differential expression
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pattern (GNA15) in our SAGE data were selected for real-time polymerase chain reaction (PCR) in
a set of HNSCC samples. Consistent with our statistical analysis, quantitative PCR confirmed the
upregulation of BST2 and MFAP2 and the downregulation of KRT31 when samples of HNSCC were
compared to tumor-free surgical margins. As expected, GNA15  presented a non-significant
differential expression pattern when tumor samples were compared to normal tissues.
Conclusion: To the best of our knowledge, this is the first study reporting SAGE data in head and
neck squamous cell tumors. Statistical analysis was effective in identifying differentially expressed
genes reportedly involved in cancer development. The differential expression of a subset of genes
was confirmed in additional larynx carcinoma samples and in carcinomas from a distinct head and
neck subsite. This result suggests the existence of potential common biomarkers for prognosis and
targeted-therapy development in this heterogeneous type of tumor.
Background
Head and neck squamous cell carcinoma (HNSCC) is one
of the most common malignancies in humans, affecting
distinct head and neck topologies including oral cavity,
oropharynx, hypopharynx, larynx and nasopharynx.
HNSCC is associated with high alcohol and tobacco con-
sumption, and represents a major international health
problem with approximately 650,000 cases and 90,000
deaths per year worldwide [1]. In Brazil, over 13,000 new
cases are expected in 2008 [2]. Currently, advances in
both surgical and nonsurgical therapeutics have led to
increased local tumor control. However, overall mortality
rates have not improved due to tumor recurrences in
regional and distant sites of the aerodigestive tract [3].
When detected early, HNSCC has a 75% 5-year survival
rate, but most patients present metastatic disease at the
time of diagnosis, which reduces survival rate to 35% [4].
This 5-year survival rate is one of the lowest among aggres-
sive cancers and has shown no significant improvement in
recent years [5,6].
Currently, there are very few molecular markers that can
be used with accuracy and reliability as indicators of head
and neck carcinomas with potential for metastatic pro-
gression, and therefore as indicators of a more aggressive
tumor behavior. A pre-operative marker, for example,
could significantly help in determining the most appro-
priate treatment for a particular patient [7]. Moreover,
changes in the gene expression profile arising exclusively
or preferentially in cancer can be used as molecular mark-
ers [8]. In fact, these markers may provide us with new
means for the early detection of cancer and cancer risk
assessment, as discussed by Hunter et al. (2005) [9] for
HNSCC.
In order to investigate molecular markers that may be rel-
evant for prognosis and therapy in cancer disease, large-
scale transcriptomic approaches such as SAGE and micro-
arrays have been extensively reported in the literature [10-
12]. In the present study, we decided to use SAGE since
this technique allows an unbiased global view of all the
transcripts expressed in a tissue sample at a given time
point. Despite its appropriateness for such studies, SAGE
is an expensive and complex technique, thus commonly
involving few and often rare biological samples.
We generated individual SAGE libraries from metastatic
(N+) and non-metastatic (N0) larynx carcinomas, and
from normal mucosa samples. A database was created to
provide absolute frequency tags for each gene in meta-
static and non-metastatic tumors, and for the normal tis-
sues. For the statistical analysis of differentially expressed
tags, the Poisson distribution was used as the basic prob-
abilistic model. The Cox partial likelihood combined with
Dempster p-values allowed us to consider an efficient sig-
nificance test to compare the Poisson means of the three
groups. Also, the choice of critical level depended on the
expression power of the tag been tested. The analysis of
the data by our statistical approach revealed subsets of dif-
ferentially expressed genes between tumor and normal tis-
sues, and between metastatic and non-metastatic
carcinomas. These differentially expressed genes deserve
further consideration as potential biomarkers for meta-
static progression, and therefore as indicators of a more
aggressive tumor behavior.
Methods
Sample preparation for SAGE and real time PCR 
experiments
Samples were frozen in liquid nitrogen and stored at -
80°C. Total RNA was extracted using TRIzol Reagent and
treated with DNase (Invitrogen Corporation, Carlsbad,
CA, USA). cDNA synthesis was performed using the High
Capacity cDNA Archive kit (Applied Biosystems, Forster
City, CA, USA) as described by the manufacturer.
The study protocol was approved by the National Com-
mittee of Ethics in Research (CONEP 1763/05, 18/05/
2005) and informed consent was obtained from all
patients enrolled.BMC Medical Genomics 2008, 1:56 http://www.biomedcentral.com/1755-8794/1/56
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SAGE
SAGE was carried out using the I-SAGE™ Kit (Invitrogen
Corporation, Carlsbad, CA, USA). Briefly, mRNA was cap-
tured from total RNA by binding to oligo (dT) magnetic
beads, and reverse transcribed with SuperScript™ II reverse
transcriptase and E. coli DNA polymerase. Bound cDNA
was cleaved with Nla III (anchoring enzyme), divided in
two fractions and ligated to adapters A and B, both con-
taining a BsmF I restriction site followed by a CATG
3'overhang, with different primer anchoring sequences at
the 5'end. Adapter linked cDNA from both fractions were
cleaved with BsmF I (tagging enzyme) to generate adapter
linked tags that were filled in by Klenow polymerase and
then mixed and ligated to form adapter linked ditags. This
mixture was used as template, in three 96-well 50 μl PCR
reactions using primers complementary to the adapters,
and the ~100-bp products were PAGE purified. Adapters
were eliminated by digestion with Nla III and PAGE puri-
fication of the 26 bp ditags that were ligated to form con-
catamers. Concatamers were submitted to polyacrylamide
gel electrophoresis and regions ranging from 300–500 bp,
500–800 bp and 800–1000 bp were purified and ligated
to pZero®-1 cloning vector. Ligation reactions were used to
transform One Shot® TOP10 Eletrocomp™ E. coli cells
using 0.2 cm cuvettes and a Gene Pulser II electroporator
(Bio-Rad Laboratories, Hercules, CA, USA) set at 2.5 kV,
25 mF and 200 Ω. Cells were plated on low salt LB agar
containing Zeocin®, in plates compatible with the auto-
mated colony picker QPix2 (Genetix, New Milton, Hamp-
shire, UK). Picked colonies were grown separately on 96-
well plates containing 2XYT media. An aliquot of each
well was then used directly in a PCR reaction, with for-
ward and reverse M13 primers. Amplified inserts were
checked and sequenced with forward M13 primer in a
MegaBACE™1000 sequencer (Amersham Biosciences, Pis-
cataway, NJ, USA) and the DYEnamic ET Dye Terminator
Sequencing Kit (Amersham Biosciences, Piscataway, NJ,
USA), or alternatively, an ABI PRISM® 377 DNA Sequencer
(Applied Biosystems, Foster City, CA) and the ABI PRISM®
BigDye™ Primer Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA, USA).
Three SAGE libraries were generated using two larynx can-
cer samples (one with lymph node metastasis or N+ and
one with no lymph node metastasis or N0) and a normal
control library pooled from two normal samples (surgical
margins from one N+ and one N0 larynx cancer). For each
library, 6,000 sequencing reactions were performed and
tags were extracted to yield approximately 100,000 tags
per library.
The raw data files are available at the Gene Expression
Omnibus database (GEO) under the accession numbers:
GSM303325 (pool of normal samples); GSM303340 (N0
tumor), GSM303349 (N+ tumor).
SAGE database
Tag frequency tables, composed of a "tag" column (10 bp
sequences) and a "count" column (number of times that
the tag appears in the library) were obtained by the
SAGE™ Analysis 2000 Software 4.0, with minimum tag
count set to 1 and maximum di-tag length set to 28 bp,
whereas other parameters were set on default. A relational
MySQL database [13] was developed to store data from
SAGE experiments. The datasets contained information
on: gene name, accession number, UniGene code, gene
symbol, absolute frequency tags in metastatic and non-
metastatic tumors and normal tissues. Other tables were
generated to store information on metabolic pathways
and gene ontology. Scripts developed in Perl [14] inte-
grated with the MySQL database allowed the identifica-
tion of genes and their respective frequencies in the three
libraries which were used as input data in the program
that performed statistical analysis. A schematic represen-
tation of databases, data analysis, and experimental vali-
dation representing our approach is shown in Figure 1.
Statistical Method
Before starting the statistical analysis, we decided to
exclude very low expression tags from the study. The
inclusion criterion considered only tags with total nor-
malized frequencies larger than 3. In order to obtain nor-
malized frequencies, the absolute frequencies in each
library were divided by the total number of tags of this
library and multiplied by the total number of tags of the
smallest library. For each tag, we observed the sum of its
three normalized frequencies. If this sum was larger than
3, it was kept in the study; otherwise, it was excluded. The
remaining tags, after this exclusion procedure, are the
object of our study (Additional file 1, Supplementary
Table 1).
Returning to the absolute frequencies of the remaining
tags, we observed that all frequencies were low in relation
to the size of the libraries. In such rare cases, the Poisson
distribution is the adequate statistical model for the anal-
ysis. In fact, the three absolute frequencies for each tag are
considered independent Poisson distributed variables.
The statistical objective at this point, for a specific tag, is
to decide whether there are differences in expression
among the libraries. We should perform statistical tests for
every tag in the data bank.
Comparing Poisson distribution is not an easy task. We
then used the Partial Likelihood method as developed by
Cox (1975) [15]. Briefly, the procedure considers the
three frequencies of a specific tag as forming an observa-
tion of a trinomial distribution, where the sample size is
now the total tag abundance, S. Representing now the
unknown trinomial probabilities of a specific tag by (p1,
p2, p3) and the total library sizes by (N1, N2, N3), homoge-BMC Medical Genomics 2008, 1:56 http://www.biomedcentral.com/1755-8794/1/56
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neity among the original three Poisson averages can be
tested by testing, in the trinomial model, the hypothesis
H: (p1, p2, p3) = (N1, N2, N3)/N where N = N1+N2+N3.
Again, we have a difficult task to compute a p-value in a
tri-dimensional sample space. Since we have distinct tag
abundances, which can go from 4 to more than one thou-
sand tags, we have to be very precise in defining the p-val-
ues. For this task, we decided to use the method developed
by Dempster (1997) [16]. The method consists of order-
ing the sample space by the likelihood ratios. To compute
the p-value, the tail area was considered as the set of all
points that have likelihood ratios smaller than those of
the observed frequencies.
Finally, as mentioned before, the tag abundances can be
very different, and considering the same significance level
would be inappropriate for the tags with low frequencies.
Following the recommendations of DeGroot (1975) [17],
we used the decision theory optimum procedure that
minimizes the risk function aα + bβ. Here, α and β are the
first and second kind of errors. In our case, we decided to
choose a = 4 and b = 1 since we believe that the first type
of error (deciding in favor of differentially expressed when
it is not) is more dangerous than the second type of error
(deciding against differentially expressed when it is).
Using simulated samples, we found that the level of sig-
nificance is a function of S, the tag abundance: α = 0.07S-
1/2.
A detailed description of the statistical method is pre-
sented in Varuzza and Pereira (2008) [18].
Functional classification of differentially expressed genes 
and online gene expression analysis
Gene ontology (GO) annotation was used for the func-
tional classification of up- and down-regulated genes. This
task was performed using terms from the Gene Ontology
database [19].
Additionally, we used the Oncomine database [20] in
order to search for a previous association of differentially
expressed genes found in this study with head and neck
cancer.
Real Time PCR
Three genes displaying down (KRT31) or upregulation
(BST2, MFAP2) were selected for validation in additional
tissues using real-time polymerase chain reaction. One
gene (GNA15) that did not present differential expression
was also selected for this validation. Their expression was
checked in 26 larynx SCC samples (15 N0 and 11 N+) rel-
ative to matched normal samples and in 36 tongue SCC
samples (18 N0 and 18 N+). The primers were manually
designed using the following parameters: 19–23 bp
length, 30–70% GC content, a short amplicon size (66–
110 bp), and at least one primer of each pair flanking an
intron-exon boundary to prevent genomic amplification
(Table 1). All primers were purchased from Invitrogen
(Brazil).
Real time PCR was carried out in a 7500 Real-Time PCR
System (Applied Biosystems). Reactions were performed
in 20 μl with 10 μl of Power SYBR® Green PCR Master Mix
(Applied Biosystems), and 400 nM of each primer. For
every experiment, 10 ng cDNA were used, and each sam-
Fluxogram showing the strategy used in SAGE data analysis Figure 1
Fluxogram showing the strategy used in SAGE data 
analysis.BMC Medical Genomics 2008, 1:56 http://www.biomedcentral.com/1755-8794/1/56
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ple was tested in triplicate. The PCR conditions were 50°C
for 2 min, 95°C for 10 min followed by 40 cycles at 95°
for 15 sec, 60°C for 1 min, 65°C for 34 sec. Following the
PCR, dissociation curve analysis was performed to con-
firm the desired single gene product.
For each primer set, the efficiency of the PCR reaction (lin-
ear equation: y = slope + intercept) was measured in trip-
licate on serial dilutions of the same cDNA sample (a pool
of 10 samples).
The PCR efficiency (E) was calculated by the formula E =
[10(-1/slope)] and ranged from 1.96 to 2.02 in the different
assays. The slope and R2 values for target and reference
genes are shown in Table 1.
Initially, five control genes were used (TUBA6,  ACTB,
GAPDH, BCR, HPRT). The GeNorm program [21] calcu-
lated stability and assumed that three genes (TUBA6,
ACTB, GAPDH) were the most appropriate.
The relative expression ratio (fold change) of the target
genes was calculated according to Pfaffl (2001) [22]. Sta-
tistical analysis was calculated by a two-tailed unpaired t
test using GraphPad prism software.
Results and discussion
Statistical analysis of SAGE data
We constructed three SAGE libraries from two larynx car-
cinoma samples and a pooled control sample aiming to
identify global events involved in tumorigenesis and
potential biomarkers in HNSCC.
Given the huge amount of data generated by SAGE, events
that play a consistent role in cancer phenotype may be
undistinguished from those that are random events, lead-
ing to false positive and false negative results. Statistical
analysis and bioinformatic tools are used to overcome
these limitations and improve the identification of a gene
expression signature of biological and therapeutic inter-
est. In the present study, we propose a statistical approach
to analyze SAGE data through the use of Poisson probabi-
listic model and the conditional test of Cox partial likeli-
hood. A Dempster methodology for ordering the sample
points of the sample spaces throughout the likelihood
ratio was also considered to compute the p-values. As the
Table 1: Primers for real time PCR, amplicon size, values of slope, PCR efficiency and linearity (R2).
Genes Primers 5' → 3' Amplicon size (bp) Slope PCR Efficiency R2
GNA15 Forward GAGAACCGCATGAAGGAGAG 84 -3.312 100.0 0.991
Reverse AAAGAGGATGACGGATGTGC
KRT31 Forward TGAGCAGGAGGTCAATACCC 110 -2.913 120.4 0.990
Reverse GACTCCTGGTCTCGTTCAGC
BST2 Forward GGAGGAGCTTGAGGGAGAG 75 -3.476 93.9 0.991
Reverse CTCAGTCGCTCCACCTCTG
MFAP2 Forward GCCGTGAGGAACAGTACCC 91 -3.152 107.6 0.990
Reverse CGGAGGCTGTAGAAGCAGAC
TUBA6 Forward TCAACACCTTCTTCAGTGAAACG 101 -3.341 99.2 0.991
Reverse AGTGCCAGTGCGAACTTCATC
GAPDH Forward ACCCACTCCTCCACCTTTGA 101 -3.392 97.1 0.990
Reverse CTGTTGCTGTAGCCAAATTCGT
ACTB Forward GGCACCCAGCACAATGAAG 66 -3.255 102.8 0.994
Reverse CCGATCCACACGGAGTACTTGBMC Medical Genomics 2008, 1:56 http://www.biomedcentral.com/1755-8794/1/56
Page 6 of 17
(page number not for citation purposes)
sample size differs considerably, we obtain the signifi-
cance critical level as a function of the tag abundance. To
order the differentially expressed genes we consider the
relative distance of the p-values against the critical level.
A total of 53,898 SAGE unique tags were obtained: 8,979
were only found in the metastatic larynx carcinoma
library, 17,588 only in the non-metastatic carcinoma
library, 15,102 only in the control library, and 12,229 tags
were expressed in at least two libraries (Additional file 1,
Tables 2, 3, 4–5). The sequences were stored in a MySQL
relational database and analyzed as shown in Figure 1.
Statistical analysis identified subsets of 1,216 differen-
tially expressed tags between tumor and normal libraries,
and 894 differentially expressed tags between metastatic
and non-metastatic carcinomas. Sixty top-up and 60 top-
downregulated tags in aggressive versus non-aggressive
tumors and in both these tumors versus normal tissues, as
well as their normalized frequencies, and the correspond-
ing genes according to SAGE Genie and SAGEmap data-
bases [23,24] are presented in Supplementary Tables 6–11
(Additional file 2).
Since several authors have reported that chi-square test is
the most appropriate for SAGE experiments [25-28], we
compared the performance of our statistical approach
(named here as Kemp method) with that of chi-square
test. For this comparison, the SAGE data set was divided
into two groups: the low-abundance tags with counts
equal and lower than 50, and the high abundance tags
expressed at higher levels (> 50). Good correspondence
between the data obtained by both tests was found for the
latter tag group (Figure 2), indicating that they are equiv-
alent for the analysis of highly expressed sequences. A
similar result was not observed for low-abundance tags
(Figure 3).
Using a proposed tag-customized critical level for both
tests, we found 341 discordant tags, which represent 4.8%
of total differentially expressed tags: 100 (29.3%) were
considered differentially expressed by chi-square test but
not by Kemp method, and 241 (70.7%) by Kemp but not
by chi-square test. Most discordant cases were low-abun-
dance tags (Additional file 3).
A tag presenting a differential expression pattern but low
counts may be considered as statistically non-significant
by methods that use fixed critical levels. Although a
number of these tags probably have biological relevance,
their selection from the SAGE data sets remains a chal-
lenge. To circumvent this limitation, Kemp's method cal-
culates the critical level of each particular tag taking into
account its total frequency, thus making the method
applicable for detecting differences in expression of tags
with counts ranging from 20 to 50. In addition, the use of
a tag-customized critical level minimizes both type I and
type II errors. Conversely, most of the statistical tests cur-
rently used to detect differentially expressed genes are
based on asymptotic results, and perform poorly for low
expression tags. Another feature of these tests is the com-
mon use of a single canonical cutoff for the significance
level (p-value) of all tags, without taking into account the
type II error.
Differentially expressed genes: biological functions and 
potential involvement in HNSCC
Information on biological processes was obtained from
the Gene Ontology (GO) database [19] for the top up-
and down-regulated genes identified by the statistical
approach (Tables 2 and 3). The data may be helpful for
evaluating their potential as drug targets and molecular
markers of cancer. Although some GO terms are not
directly related to tumorigenesis, as lipid metabolism
process and viral genome replication, they provide evi-
dence of some important changes in cell metabolism cou-
pled to energy generation and cell growth [29].
The functions of up-regulated genes in tumors include sig-
nal transduction (BST2,  FLNB,  GNAI2), transcription
(NRG1), anti-apoptosis (ANGPTL4,  CCL2,  IFI6), cell
adhesion (SAA1), cell migration and angiogenesis
(MYH9), epidermis development and keratinization
(COL1A1, COL7A1, KRT14, LAMC2, S100A7), and prote-
olysis (MYH9). Down-regulated genes are also involved in
signaling (CD24, DBNL, ECM1, TNFSF10, TSPAN6), tran-
scription (EHF, PTRF), anti-apoptosis (SERPINB2), kerat-
inocyte differentiation, keratinization and epidermis
development (EHF, KRT13, SPRR3, TGM3, CRABP2), and
inflammatory response (ANXA1, S100A9). Comparison
of aggressive (N+) and non-aggressive (N0) larynx tumors
also showed interesting differences, including up-regula-
tion of NRG1, a ligand for the receptor tyrosine kinase
ErbB3 and 4 [30,31], and down-regulation of IGFBP3 and
keratin 6A (KRT6A) in N+ tumor. The latter result is inter-
esting since K6-null mice exhibit changes in the oral
mucosa resembling those of congenital pachyonychia
[32]. In addition, K6a/K6b double-null mice also show
localized disintegration of the dorsal tongue epithelium
[33]. In relation to IGFBP-3, which has pro-apoptotic
properties [34], reduced expression has already been
found in tongue SCC cases, and associated with signifi-
cantly shorter disease-specific and disease-free survival
[35]. The authors have suggested that its down-regulation
is an early event in head and neck tumorigenesis, with
adverse prognostic significance in tongue cancer, and may
represent a marker of aggressive disease, reinforcing the
results of the present study.BMC Medical Genomics 2008, 1:56 http://www.biomedcentral.com/1755-8794/1/56
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Table 2: Information on biological processes based on Gene ontology. 
Biological Process Up-regulated genes
Cell communication
signal transduction ARHGAP29, BST2, CCL2, CXCL14, CMIP, FLNB, GNAI2, LY6E
cell-cell signaling BST2, CCL2
Transcription MZF1, NRG1, RP13-122B23.3, ZNF452
Translation RPS15, RPS23
Apoptosis INCA
induction BID
anti-apoptosis ANGPTL4, CCL2, IFI6, XAF1
Cell adhesion AJAP1, CCL2, MSLN, SAA1
Cell migration MYH9, SAA1, LUM
Cell cycle PLK1
Cell division MYH9
Cell proliferation BOLA2, BST2, PLK1
Cellular development process
cell differentiation MYH9
keratinocyte differentiation S100A7, SPRR2F
Cellular structure morphogenesis MYH9
Developmental process BST2, SPRR2F
organ development CCL2, MEPE, SPARC
epidermis development COL1A1, COL7A1, KRT14, LAMC2, S100A7, SPRR2F
keratinization SPRR2F
Response to stimulus
defense response
inflammatory response IL1F5, SERPINA3
immune response BST2, CCL2, IFI6, IFITM2, IL1F5, SEMA3C
response to stress DTL, SGK
response to oxidative stress S100A7
response to external stimulus CXCL14, CCL2, GNAI2, S100A7, SAA1, SEMA3C, TOPBP
Angiogenesis ANGPTL4, MYH9
Transport MYH9, NEFL, RBP1, SGK, SLC15A3, SLC6A8
Metabolic process NADK
protein metabolic process INCA, LEPREL1, MYH9, NRG1, PRSS21, PSMC1
protein modification process CCL2, DTL, FKBP9L, HSPE1, ISG15, SGK, TOR3A
lipid metabolic process APOC1, APOL1, CEL, PLA2G4E, PTGS1, SERPINA3
carbohydrate metabolic process NANS
DNA metabolic process DTL, H3F3B
nucleic acid metabolic process 0ERH
RNA processing LSM4, SNRPD3
Cytoskeleton organization FLNB, MYH9, NEFL, PLEK2
Extracellular structure organization LUMBMC Medical Genomics 2008, 1:56 http://www.biomedcentral.com/1755-8794/1/56
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Viral genome replication CCL2
Cellular homeostasis CCL2, IFI6, SAA1, SELT
No classification BASP1, CCNYL1, F8A1, FGFBP2, GRAMD1B, IFI27, KIAA1467, KIAA1799, KRTDAP, MFAP2, MSMB, NOL6, 
OLFML2A, SNCG
Down-regulated genes
Cell communication
signal transduction ANXA1, ARHGAP27, CD24, CRABP2, DBNL, ECM1, GPR126, IL6R, MAL, TNFSF10, TSPAN6, TYRO3
cell-cell signaling CD24, MAL, S100A9, TNFSF10
Transcription CRABP2, EHF, HOP, PTRF
Apoptosis
induction CLU, MAL, TNFSF10
anti-apoptosis ANXA1, SERPINB2
Cell adhesion CLDN4, TYRO3
Cell migration ANXA1, CD24, PRSS3
Cell proliferation IL6R, EHF
positive regulation CLU, TSPAN31, CD24
Cellular development process
cell differentiation CLU, HOP, KRT19, MAL
keratinocyte differentiation A2ML1, ANXA1, SPRR3, TGM3
epithelial cell differentiation EHF
Developmental process EHF, IL6R, MAL
organ development CLU, HOP, MAL
ectoderm development KRT6A
epidermis development CRABP2, KRT13, SPRR3, TGM3
epidermal cell differentiation
keratinization CNFN, PPL, SPRR3
Response to stimulus
defense response NCF1
inflammatory response ANXA1, LYZ, MGLL, S100A8, S100A9
immune response CLU, CR1, GBP6, IL1RN, IL6R
response to stress CD24, CLU
response to external stimulus CAT, CD24, CSTB, KRT8, PDE6B, SPRR3
Transport ALDH3A1, AQP5, ARHGAP27, CAT, CD24, KIF1C, PGD, PLLP, RHCG, SPNS2
Metabolic process ALDH3A1, CD24, ECHDC3, TPI1
protein metabolic process PRSS3, RANBP9, TMPRSS11E, UBR4, USP10
protein modification process ANXA1, PRSS3, TGM3, USP10
lipid metabolic process AKR1C2, ANXA1, APOD, CLU, LTB4DH, MGLL, PIGF, TPI1
carbohydrate metabolic process PGD, TPI1
Lymphocyte activation CD24
Homeostasis RHCG, CD24
Table 2: Information on biological processes based on Gene ontology.  (Continued)BMC Medical Genomics 2008, 1:56 http://www.biomedcentral.com/1755-8794/1/56
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No classification C20orf149, C6orf205, C9orf58, CAPNS2, CRCT1, DIS3L2, FAM129B, GPRASP2, HPCAL1, IER2, IGHA1, 
KRT78, LOC342897, LOC643008, LYPD2, LYPD3, MGC59937, MUC1, NUCKS1, PRH1, TMEM59, TPPP3, 
ZFAND1
Top up- and down-regulated genes selected from SAGE in tumor samples compared to normal samples.
Table 2: Information on biological processes based on Gene ontology.  (Continued)
Table 3: Information on biological processes based on Gene ontology.
Biological Process Up-regulated genes
Cell communication
signal transduction CXCL14, OR4S2, RPS6KA1, TNFRSF18, TNFSF10
cell-cell signaling TOLLIP
Transcription NRG1, SUMO1
Apoptosis INCA
induction TNFSF10
anti-apoptosis PRKCZ, TNFRSF18
Cell-adhesion MSLN
Cell cycle CCND1, UBE2C
Cell proliferation
negative regulation EMP3
Cellular development process
cell differentiation KRT19
Developmental process
organ development KRT19
epidermis development
Response to stimulus
defense response
inflammatory response SERPINA3
response to stress
response to oxidative stress GPX2
response to external stimulus CXCL14, OR4S2
Transport HBB
Metabolic process NADK
protein metabolic process DKFZP586H2123, INCA, NRG1, SULF2, UBE2C, USP9X
protein modification process CCND1, POMT2, PRKCZ, SUMO1, USP14
lipid metabolic process SERPINA3
carbohydrate metabolic process DCXR
RNA metabolic process PCBP2
RNA processing RBM17
DNA repair SUMO1
No classification: ANXA7, BRD9, C6orf148, CMIP, FLJ23577, LOC283516, LOC283731, LOC388796, MFAP2, RRP15, SNCG, 
TMEM109, ZC3H7BBMC Medical Genomics 2008, 1:56 http://www.biomedcentral.com/1755-8794/1/56
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Potential molecular markers identified by SAGE: 
Validation by Real-Time PCR
The selection of genes for validation by real-time RT-PCR
was carried out after an extensive literature analysis of
gene expression studies of head and neck carcinomas
[3,4,36-66]. The following criteria were used for gene
selection: (i) potential involvement in cancer develop-
ment or aggressiveness and a yet unclear role in HNSCC
tumorigenesis, and (ii) similar expression pattern in data
reported in the literature as well as in our SAGE experi-
ments.
Using these criteria as guidelines, four genes were selected:
two with a pronounced overexpression in SAGE tumor
libraries (BST2 and MFAP2), one with an intermediate
downregulation profile (KRT31, also referred to as
Down-regulated genes
Apoptosis KLK8
induction IGFBP3
anti-apoptosis ANGPTL4
Cell adhesion SAA1
Cell migration SAA1
Cell cycle
Negative regulation KLK10
Cell proliferation
Negative regulation FGFBP1
keratynocyte proliferation KLK8
Cellular development process
cell differentiation IGFBP3, KLK8, SPON2
keratinocyte differentiation SPRR2E, SPRR2F, SPRR3
Developmental process SPRR2E, SPRR2F
organ development
ectoderm development KRT6A
epidermis development SPRR2E, SPRR2F, SPRR3
keratinization SPRR2E, SPRR2F, SPRR3
Response to stimulus
defense response NCF1
inflammatory response PI3, S100A8, S100A9,
immune response DEFB4, HLA-A, PI3, TAPBP
response to stress HIG2, KLK8
response to external stimulus KLK8, SAA1
Angiogenesis ANGPTL4
Transport ALDH3A1, HBA2, PGD
Metabolic process ALDH3A1, TPI1
protein metabolic process TAPBP
protein modification process CCT3, FKBP9L, HSPE1, IGFBP3
lipid metabolic process PLA2G4E, TPI1
carbohydrate metabolic process PGD, TPI1
Cellular homeostasis SAA1
No classification C10orf99, C9orf58, CAPNS2, FAM129B, GPRASP2, IGHA1, LMNA, LOC645960, LYPD2, MUC1, NOL6, PSME2, 
SLFN13, SNHG8, TJP2, TncRNA
Top up- and down-regulated genes selected from SAGE in N+ tumor sample compared to N0 sample.
Table 3: Information on biological processes based on Gene ontology. (Continued)BMC Medical Genomics 2008, 1:56 http://www.biomedcentral.com/1755-8794/1/56
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KRTHA1) and one with a non-significant differential
expression pattern (GNA15).
According to the statistical analysis performed, BST2 and
MFAP2 tags were expressed at high levels in tumors com-
pared to normal tissues (at least 13-fold or higher), the
latter also exhibiting a remarkable overexpression in N+
samples in relation to N0 samples. The normalized fre-
quencies of BST2 tags showed N+ tumor/normal and N0
tumor/normal ratios of 15.8 and 24.3, respectively. For
MFAP2, N+ tumor/N0 tumor and N+ tumor/normal
ratios were 25.3 and 13.5, respectively. In contrast to these
genes, GNA15 showed no differences in gene expression
between samples analyzed by SAGE and was selected as a
negative control. Although classified as a relevant under-
expressed candidate marker in tumors by the statistical
analysis of SAGE data, KRT31 displayed less expressive
differences between N+ or N0 tumors and normal tissues.
The normalized frequencies of tags are shown in Supple-
mentary Tables 6–11 (Additional file 2). Similar expres-
sion patterns of BST2, MFAP2, KRT31 and GNA15 tags
were observed by using a chi-square test.
The expression data for the selected genes were validated
in 15 pairs of tumor and matched normal tissues from N0
LSCC and 11 pairs from N+ LSCC. The data were also val-
idated in another head and neck subsite by using 36 pairs
of tumor and matched normal tissues from tongue squa-
mous cell carcinomas (18 N+ and 18 N0). MFAP2 was
upregulated (≥ 2 fold) and KRT31 was downregulated (≥
2-fold) in both N+ and N0 laryngeal tumors versus nor-
mal samples, the former also in tongue tumors. BST2 gene
was also upregulated but only in N0 tumors versus nor-
mal tissues. No difference between N+ and N0 carcinomas
was detected for these genes, except for MFAP2 in tongue
samples. According to SAGE expression profiles, GNA15
exhibited a non-significant differential expression pattern
in carcinomas versus normal tissues, except between N+
and N0 tumors (Figure 4).
The results of the real time PCR experiments were, there-
fore, in agreement with SAGE data. However, as PCR
experiments were performed using a larger number of
cases than SAGE, we observed high variability of gene
expression among the samples. This finding suggests
Chi-square p-value versus Kemp value for high-abundance tags Figure 2
Chi-square p-value versus Kemp value for high-abundance tags.
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molecular heterogeneity in HNSCC, as previously stated
by Mendez et al. (2002) [55].
The selected genes present intriguing functions related to
normal and neoplastic development. KRT31  gene, for
example, encodes a type I hair keratin, which is specifi-
cally expressed in hair and nails but has been previously
observed in normal keratinocytes from buccal mucosa
[67]. In cancer, loss of differentiation-specific hair kerat-
ins was found in late-stage pilomatrixoma, a skin tumor
of follicular origin [68]. Since, keratin 31 has been
detected in normal oral mucosa, a similar change in its
expression pattern may occur in mucosa-derived squa-
mous carcinomas.
The BST2  gene encodes the bone marrow stromal cell
antigen 2, a transmembrane glycoprotein potentially
involved in interactions between cancer cells and bone
marrow stromal cells and related to angiogenesis, cell pro-
liferation and chromosomal instability [69]. The BST2
promoter region contains putative cis  elements for
GATA1, STAT 3 and 1 transcription factors, the latter over-
expressed in HNSCCs [70]. BST2 up-regulation has been
observed in multiple myeloma, non-Down syndrome
(DS) acute megakaryocytic leukemia, tamoxifen-resistant
breast cancer [71-73] and, in the present study, was upreg-
ulated in HNSCC samples. Stromal cells prevent chemo-
therapy-induced apoptosis of leukemia cells [74]. The
findings of Ge et al. (2006) [73] suggest that BST2 could
potentially participate in the leukemia-cell protection
from ara-C-induced cytotoxicity mediated by bone mar-
row stromal cells. These data and the findings of Becker et
al.  (2005) [72] on BST2  overexpression in tamoxifen-
resistant breast cancer indicate that BST2 may possibly
represent a new therapeutic target for leukemia as well as
for other types of cancer, including HNSCC.
The MFAP2 or MAGP-1 gene encodes the microfibrillar-
associated protein 2, a small molecular weight compo-
nent of extracellular microfibrils, which are structural ele-
ments of elastic tissues in the lungs, skin, and vasculature.
Miyamoto et al. (2006) [75] showed that MAGP-1 protein
Chi-square p-value versus Kemp value for low-abundance tags Figure 3
Chi-square p-value versus Kemp value for low-abundance tags.
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Gene expression in metastatic (N+) and non metatastic (N0) tumors Figure 4
Gene expression in metastatic (N+) and non metatastic (N0) tumors. Expression of BST2, MFAP2, KRT31 and 
GNA15 was determined by real-time PCR in (A) 26 pairs of larynx tumors and matched normal tissues (15 N0 and 11 N+) and 
(B) 36 pairs of tongue tumor and matched normal samples (18 N+ and 18 N0). Relative quantitation of target gene expression 
for each sample was calculated according to Pfaffl [22]; GAPDH was used as the internal reference and normal sample as the 
calibrator. Values were Log2 transformed (y-axis) so that all values below -1 indicate down-regulation in gene expression while 
values above 1 represent up-regulation in tumor samples compared to normal samples. Differences in gene expression 
between groups (N0 and N+) were calculated by unpaired t test using GraphPad prism software and were considered statisti-
cally significant at P < 0.05 (*). The error bar represents the mean ± S.E.M (standard error of the mean).BMC Medical Genomics 2008, 1:56 http://www.biomedcentral.com/1755-8794/1/56
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can bind to the Notch1 receptor, leading to a subsequent
signaling cascade. In self-renewing tissues and during
tumorigenesis, Notch signaling may inhibit differentia-
tion, lineage specification at developmental branch points
and induction of differentiation. For example, Notch sig-
naling regulates binary cell fate decisions in the develop-
ment of the peripheral nervous system in flies. Equipotent
precursors give rise to two alternative cell fates: epidermal
or neuronal, depending on whether a progenitor cell
receives a strong or weak Notch signal. In the skin, Notch
induces terminal differentiation of keratinocytes. There-
fore, the Notch pathway may lead to different and some-
times opposing outcomes. One explanation is that Notch
function is context-dependent [76]. Abnormal Notch acti-
vation has been observed in different tumors [77-80]
although growth suppression has also been noticed after
constitutively over-expressed active Notch1 [81]. Thus,
Notch signaling can function as both an oncogene and a
tumor suppressor, even within a single tumor, supporting
the idea that the Notch1 pathway is cell-type specific and
context-dependent [82].
It is noteworthy that all these three genes (BST2, KRT31,
MFAP2) and 27 differentially expressed genes referred to
above (ANGPTL4,  ANXA1,  CCL2,  CD24,  COL1A1,
COL7A1,  CRABP2,  DBNL,  ECM1,  EHF,  FLNB,  GNAI2,
IFI6,  KRT13,  KRT14,  LAMC2,  MYH9,  NRG1,  PTRF,
S100A7,  S100A9,  SAA1,  SERPINB2,  SPRR3,  TGM3,
TNFSF10, TSPAN6) presented the same expression pat-
tern in Oncomine data sets and in our analysis, except two
genes which exhibited a different pattern (NRG1,
TNFSF10) and five genes with no information in head
and neck data sets available through Oncomine
(ANGPTL4, FLNB, DBNL, IGFBP3, PTRF).
Overall, the results of the real time PCR experiments
showed consistent patterns in HNSCC patients and were
in agreement with SAGE analysis. However, little is
known about changes at the protein level, and the rela-
tionship between gene expression and tumor phenotype
as well as the potential value of these genes as biomarkers
for HNSCC tumorigenesis should be evaluated in future
studies.
Conclusion
To the best of our knowledge, this is the first study report-
ing SAGE data in head and neck squamous cell tumors.
The analysis of SAGE data by our statistical approach was
effective in identifying differentially expressed genes
reportedly involved in cancer development. In agreement
with our statistical analysis, three genes (BST2, MFAP2
and KRT31) selected for validation experiments were dif-
ferentially expressed in an independent subset of HNSCCs
compared to normal tissues or in metastatic versus non-
metastatic samples. The selected genes have not been pre-
viously implicated in head and neck tumorigenesis. In
addition, our data suggest a role for Notch signaling in
HNSCC tumorigenesis, together with factors involved in
keratinocyte differentiation, keratinization and epidermis
development. The confirmation of the differential expres-
sion of this subset of genes selected from LSCC SAGE
libraries in other HNSCC sites reinforce the existence of
potential common biomarkers for prognosis and targeted
therapy of such tumors.
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